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Summary
Proteasomes degrade endogenous proteins in the cytosol. The potential contribution of the
proteasome to the effect offlanking sequences on the presentation ofan antigenic epitope pre-
sented by the major histocompatibility complex class I allele Ld was studied. Peptides generated
in cells from minigenes coding for peptides of 17- and 19-amino acid length were compared
with the in vitro 208 proteasome degradation products of the respective synthetic peptides.
The quality o£generated peptides was independent of ubiquitination. In vivo and in vitro pro-
cessing products were indistinguishable with respect to peptide size and abundance . Altering
the neighboring sequence substantially improved the yield of the final antigenic nonapeptide
by 20S proteasome cleavage . These results suggest that, in addition to the presence of major
histocompatibility complex class I allelic motifs, the cleavage preference ofthe proteasome can
define the antigenic potential of a protein .
n the MHC class I pathway of antigen presentation, pro-
teins are degraded in the cytosol, and resulting peptides
are transported into the endoplasmatic reticulum, where
they assemble with the MHC class I heavy chain and R2-
microglobulin to the trimolecular MHC complex. This
complex is subsequently exported to the plasma membrane
to be recognized by peptide-specific CTL. Insertion of the
sequence coding for the antigenic peptide into unrelated
proteins does not prevent processing and presentation (1) .
However, the insertion of the sequence of the murine
CMV (MCMV)1-derived 16aYPHFMPTNL' 16 peptide (2)
into the hepatitis B virus e-protein (HBe) revealed a strong
positional effect in antigen processing, which could be res-
cued by flanking the epitope with multiple alanines (3).
This modulatory effect of flanking sequences has also been
seen using constructs expressing peptides of influenza pro-
teins (4, 5) .
There is evidence that the proteasome is involved in an-
tigen processing. Two subunits of the proteasome, LMP2
and LMP7, are encoded in the MHC (6-9), and mice lack-
ing LMP7 (10) are compromised with respect to MHC
class I molecule expression and antigen expression (11) . In-
hibitors of the proteasome block the generation ofpeptides
presented by MHC class I molecules (12) . Expression of a
protein fused to ubiquitin improved antigen presentation
'Abbreviations used in this paper: HBe, hepatitis B virus e-protein; LLnL,
N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal; LMP, low molecular weight
protein; MCMV, murine CMV; MG-132, N-carbobenzoxyl-L-leucinyl-
L-leucinyl-L-norvalinal.
(13) . Furthermore, processing of a complex protein re-
quired ubiquitination (14) for degradation by the prote-
asome in vivo. The effect of flanking residues on the
presentation of YPHFMPTNL may be associated with
ubiquitination and the proteasome degradation pathway.
We find that the positional effect of flanking amino acids
operates in absence of ubiquitination. The comparison of
the peptides generated in vivo and in vitro shows that the
positional effect on antigen presentation can be completely
explained by the function of the 20S proteasome.
Materials and Methods
Recombinant Vaccinia Viruses.
￿
Recombinant vaccinia viruses
were generated according to Del Val et al. (3). The minigenes
were generated by PCR of the corresponding chimeric HBe
gene starting with an initial methionine. The recombinant mini-
genes were coding for a 17-mer (MDIGYPHFMPTNLGDPY)
or a 19-mer (MDIGAYPHFMPTNLAGDPY). The fidelity of
genetic engineering procedures was confirmedby DNA sequence
analysis of plasmid inserts. Genes were inserted into the TK locus
ofvaccinia virus by homologous recombination,
Cytolytic Assay of Naturally Processed Peptides.
￿
BALB.SV cells
were infected with recombinants at amultiplicity ofinfection of 4
PFU per cell for 7h. Infected cells served as targets in a standard 5'Cr
release assay. The specific CTL generatedby in vitro restimulation
with 10-e M nonapeptide were added in graded numbers (3).
Data represent the mean percentage from six replicate cultures.
Isolation of Naturally Processed Peptides.
￿
Naturally processed
peptides were extracted from cells as described by R6tzschke et
al. (15). Briefly, TFA-soluble material was separated first on a
Sephadex G25 column and subsequently on an HPLC reversed-
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many) . Eluent A was 0.1% TFA; eluent B was 70% acetonitrile
containing 0.1% TFA . The gradient was 25-90% eluent B in 14
min, the flow rate was 0.8 ml/min-', and fraction size was 0.8
ml . Fractions were resuspended and diluted in RPMI 1640 me-
dium . 51 Cr-labeled P815 cells were added and, after 1 h ofincu-
bation, probed by CTL . Fractions were tested in triplicate . The
nonapeptide elutes in fraction 15 and the noncleaved minigene
products elute in fraction 19 .
Assay of Proteolytic Activity .
￿
20 pg of the synthetic polypep-
tides (MDIGYPHFMPTNLGDPY; MDIGAYPHFMPTNLA-
GDPY) and 1 la ,g of 20S proteasome from BALB.SV cells pre-
pared according to Boes et al . (16) were incubated at 37 °C for 24 h
in a total volume of 300 VI assay buffer (20 mM Hepes/KOH,
pH 7.8, 2 mM MgAc2 , 1 mM dithiothreitol) . After titration of
the digestion mixture in 10-fold dilution steps (10-6-10-12 M)
the specific lysis was determined by 51Cr release assay . Incubation
was performed either with 5% FCS in RPMI 1640 or under se-
rum-free conditions using 5% BSA in RPMI 1640 . The increase
in antigenicity was calculated from the half-maximal lysis of the
linear range of the regression curve . The nonapeptide served as a
standard .
Mass Spectrometric Analysis .
￿
10 1d of proteasome digest was
separated by reversed-phase HPLC (SMART-System equipped
with a N.RPC C2/C18 SC 2.1/10 column ; Pharmacia LKB)
(eluent A, 0.1% TFA; eluent B, 70% acetonitrile containing
0.09% TFA; gradient, 20-95% eluent B in 15 min, flow rate 50
p,l/min-1 ) and analyzed on-line by a tandem quadrupole mass
spectrometer (model TSQ 7000; Finnigan MAT, Bremen, Ger-
many) equipped with an electrospray ion source . Each scan was
acquired over the range mass/charge (m/z) 300-1,300 in 2 s . The
sequences of the major cleavage products were determined by
fragmentation of peptides with argon atoms in tandem mass ex-
periments . Less-abundant peptides were identified by calculation
of the molecular mass from the m/z peaks of the double-charged
ions and coelution with synthetic peptides of potential cleavage
products . The amount of peptides was determined by the inten-
sity of the ion current ofthe double-charged ions using the syn-
thetic peptides as a standard .
Proteasome Inhibition Assay.
￿
Inhibitor studies were done with
1 Ltg of proteasome using 20 wg of the 19-mer peptide in 300 Nd
of assay buffer as described above, adding 5-50 [LM of the alde-
hyde inhibitors N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal (LLnL)
(Sigma Chemical Co ., St. Louis, MO) or N-carbobenzoxyl-L-
leucinyl-L-leucinyl-L-norvalinal (MG-132, similar to MG-115
[12]) (Myogenics, Cambridge, MA) . After 24 h at 37 °C, the sam-
ples were subjected to mass spectrometry analysis . Thepercentage
ofinhibition was calculated from the intensity of the main degra-
dation products (YPHFMPTNL andMDIGAYPHFMPTNL) .
HPLC Separation of Processed Peptides .
￿
50 p,l of the digest was
separated by reversed-phase HPLC as described in mass spectro-
metric analysis but using another gradient (5-50% B in 30 min,
50-95% B in 10 min, flow rate 100 ltl/min-1 ) . 100-p,1 fractions
were collected . For the quantification of the antigenicity of the
fractions, 10-fold dilutions were tested in triplicate in a 3-h "Cr
release assay. The antigenic peptides were identified by mass spec-
trometry and by coelution of synthetic peptides . The activity of
the 10-2 dilution is shown in Fig . 5 .
Results and Discussion
To compare antigen processing in cells with peptide
degradation in vitro by the 20S proteasome, two minigenes
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coding for short peptides were constructed . One minigene
codes for a 19-mer peptide representing the antigenic
MCMV epitope, a biterminal alanine spacer, and the local
flanking amino acids ofMe (tMDIGAYYPHFMPTNLA-
GDPY 19). The other minigene encodes a 17-mer peptide
( 1MDIGYYPHFMPTNLGDPY 17 ) without the alanines .
The minigenes were expressed in cells by recombinant vac-
cinia viruses. As a first step, antigen presentation from mini-
gene products was compared with complete HBe proteins .
As observed before (3), alanine spacing at both termini of
the naturally processed nonamer sequence, YPHFMPT _NL,
improved antigen presentation . Extending previous data
using multiple alanines, a single biterminal alanine was also
sufficient (Fig. 1 A) . Thus, the minigenes also showed a
positive alanine effect on antigen presentation . There was
no detectable quantitative difference with respect to anti-
gen presentation between minigenes and the HBe con-
structs . Whereas recombinant HBe should be susceptible to
ubiquitin-dependent degradation, minigenes expressing
short peptides that lack lysine residues important for ubiq-
uitination (17) should not. Therefore, the positional effect
on antigen presentation operates independentlyofubiquiti-
nation ofthe antigenic polypeptide .
Total extracts from cells infected with the vaccinia re-
combinants were separated by reversed-phase HPLC to as-
sociate the biological activity with defined peptides . P815
target cells were incubated with individual HPLC fractions
to allow peptides to associate with Ld molecules and then
exposed to nonapeptide-specific CTL. These CTL detect
not only the MCMV nonapeptide but also related peptides
(2) . Only the results for the extracts from cells expressing
the minigenes are shown, because the data with the chimeric
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Figure 1 .
￿
Rescue o£ antigen processing and presentation by alteration
of sequences flanking the epitope. (A) The nonapeptide sequence "sYPH-
FMPTNL 1'6 of theMCMV IEl protein, which is naturally presented by
theMHC class I allele Ld (2), with (open circles) and without (open triangles)
flanking alanines was inserted close to the NH 2 terminus of the HBe pro-
tein . Similarly, rninigenes coding for parts of this sequence (MDIGAY-
PHFMPTNLAGDPY Milled circles] and MDIGYPHFMPTNLGDPY
[filled triangles]) were constructed and tested for antigen presentation by
specific CTL . HBe-vac (open diamonds) served as negative control . (B and
Q Detection by CTL ofnaturally processed antigenic peptides extracted
from cells infected with recombinant minigenes expressing the 17-tner
MDIGYPHFMPTNLGDPY (B) or the 19-mer MDIGAYPHFMPT-
NLAGDPY (Q .
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￿
Increase in antigenicity after degradation of synthetic pep-
tides by the 20S proteasome. The synthetic peptides MDIGAY_PH-
FMPTNLAGDPY (circles) and MDIGYPHFMPTNLGDPY (triangles)
were incubated with 20S proteasome. The antigenicity ofdigestion prod-
ucts (flied symbols), undigested peptides (open symbols), and the nonapep-
tide YPHFMPTNL (open squares) were quantified by s1 Cr release assay
under serum-containing (A) and serum-free (B) conditions.
HBe proteins after biterminal flanking with one alanine
were essentially identical to previously reported data (3) .
All constructs generated biological activity that coeluted
with the synthetic nonapeptide. Dilution of active fractions
HPLC-chromatogram 4
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HPLC-chromatogram
(data not shown) showed that the peak generated from ala-
nine-flanked constructs reproducibly yielded -25-fold
more activity (Fig. 1, B and Q . Furthermore, additional
peaks of activity coeluted at a position of full-length 17-
mer and 19-mer peptides. These additional peaks were not
seen with the full-length HBe constructs.
The effect of alanine spacing on peptide presentation
could either reflect differences in degradation, transport, or
a combination ofboth effects. Degradation of polypeptides
by 20S proteasome in vitro has been studied in previous re-
ports (16, 18, 19) . To test whether sequence differences
can alter the proteasome cleavage preference in vitro, the
two synthetic peptides of 17-mer and 19-mer substrates
were analyzed for biological activity after proteasome di-
gestion (Fig. 2) .
It has been observed before (20) that some longer pep-
tides, in the reported example a 16-mer peptide, can be
bound to MHC class I molecules for CTL recognition, but
that the natural ligand is recognized 1,000-fold better. Ac-
cordingly, the undigested 17-mer and 19-mer substrates
had little activity, and at least 10-s M of peptide was re-
quired for target cell formation, whereas the natural processed
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Characterization of proteasome digestion
products by mass spectrometry. 20S proteasome-
degraded peptides of the 17-mer (A) and the 19-mer
(B) were separated by reversed-phase HPLC and ana-
lyzed on-line by mass spectrometry for identification of
individual peptides in complex mixtures of distinct
peptides (22) . The separation is documented by the
HPLC chromatogram (4) and by the ion current of
twofold positive-charged peptide ions detected by mass
spectrometry (1-3). A1 and Bl (m/z 560.5) show the
mass peak ofthe nonapeptide YPHFMPTNL, A2 (m/z
768.4) the 13-mer MDIGYPHFMPTNL, and B2 (m/z
803.9) the 14-mer MDIGAYPHFMPTNL. The re-
maining uncleaved substrates are shown in A3 (m/z
984.5) MDIGYPHFMPTNLGDPY and B3 (m/z
1,055.5) MDIGAYPHFMPTNLAGDPY.
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￿
Effect ofpeptide aldehydes on the peptide-degrading activity
of 20S proteasomes . The synthetic 19-mer (MDIGAYPHFMPT-
N_LAGDPY) was subjected to 20S proteasome digestion in the presence
ofincreasing concentrations of inhibitor . The reduced yield of the main
cleavage products YPHFMPTNL and MDIGAYPHFNPTNL is ex-
pressed as the percentage ofinhibition.
nonamer is reactive at a concentration between 10- it and
10-12 M . 20S proteasome incubation of the 17-mer pep-
tide led only to a fourfold activity increase (Fig. 2 A) .
However, the effect on the alanine-flanked peptide was
striking, and the activity increased 160-fold .
Sherman et al. (21) reported that under certain condi-
tions a serum protease, angiotensin-converting enzyme,
can contribute to the activation of an inactive peptide by
removing a COOH-terminal dipeptide. To test the poten-
tial proteolytic degradation of proteasome products by se-
rum components, the external loading of the peptides and
the detection of the biological activity was carried out un-
der serum-free conditions (Fig. 2 B) . There were no differ-
ences between presence or absence of serum . We conclude
that the processing of the external loaded peptides was en-
tirely due to the function of the proteasome .
To characterize major degradation products and to iden-
tify individual peptides in the digests, the materials were
separated by HPLC and analyzed on-line by mass spec-
trometry (22) (Fig. 3) . Only 31% of the 17-mer substrate
was degraded . This was not due to substrate length or pro-
teasome activity . The 13-mer MDIGYPHFMPTNL rep-
resented the main cleavage product . At the position of the
nonapeptide YPHFMPTNL , no signal was detectable . In
contrast, the 19-mer peptide was almost completely di-
gested (98%) . The 14-mer MDIGAYPHFMPTNL was
identified as the major product (63%) . The antigenic nona-
peptide constituted 17% of the products and explained the
strong increase in biological activity .
To consider the potential contribution of contaminating
proteases, the 20S proteasome degradation of the 19-mer
was carried out in the presence ofthe peptide aldehyde 20S
proteasome inhibitors LLnL and MG-132, described by
Rock et al . (12) (Fig . 4) . The mass spectrometry analysis of
Figure 5 .
￿
CTL recognition of20S proteasome-degraded peptides . The
yield and the identity of antigenic peptides processed by the 20S protea-
some from the 17-mer (A) and 19-mer (B) were probed by nonapeptide-
specific CTL . The OD curve and the specific lysis (gray columns) are
shown for individualHPLC fractions .
the major degradation products YPHFMPTNL and MDI-
GYPHFMPTNL revealed a strong inhibition, almost 100%
ofthe 20S proteasome by the potent inhibitor MG-132 . As
already observed by Rock et al ., the inhibition of the pro-
teasome by LLnL was weaker. These data emphasize that
the observed processing o£ the peptide substrates represents
a 20S proteasome function .
To identify the peptides responsible for the biological ac-
tivity, the antigenicity of degradation products was analyzed
after reversed-phase HPLC separation . In the 17-mer di-
gest, the CTL detected an activity in fraction 26 (Fig . 5 A),
where both substrate and 13-mer (MDIGYPHFMPTNL )
coelute . Therefore, the additional peak detected in cell ex-
tracts from minigenes (Fig . 1, B and C may also contain
the full-length peptide and related cleavage products . Both
peptides have low intrinsic antigenicity and are only recog-
nized because of their large quantity .
The activity in fraction 23 comigrates with the antigenic
nonapeptide YPHFMPTNL . Thus, only a minor fraction
of the 17-mer peptide is processed to the nonapeptide .
Analysis ofthe 19-mer digest (Fig. 5, B) identified the ma-
jor product MDIGAYPHFMPTNL in fraction 26 . The
bulk ofthe biological activity resides in fractions 22 and 23,
where YPHFMPTNL andAYPHFMPTNL coelute . Ac-
cording to mass spectrometry, the 10-mer constitutes only
5% of the products (not shown) . The activity in fraction 20
coelutes with a peptide whose molecular mass is 16 mass
units higher than the nonapeptide . The assumption that the
methionine o£ this peptide is oxidized was confirmed by
coelution with the oxidized synthetic peptide, YPH-
FMPTNL(ox) . Thus, the sequence alterations affecting an-
tigen presentation in vivo are truly reflected by the in vitro
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a naturally processed nonamer.
In vitro, the 20S proteasome degrades polypeptides pro-
gressively (18). Resulting peptides have a size range appro-
priate for MHC class I binding (23), and antigenic peptides
that are naturally presented by MHC molecules are among
the degradation products (17, 19). Induction of the MHC-
linked LMP products alters the composition and cleavage
specificity of the proteasome (17, 24, 25) . The 205 protea-
some constitutes the proteolytic core of the 26S complex,
which is essential in the ATP-ubiquitin-dependent degra-
dation pathway (26, 27) . The claimed ubiquitin depen-
dence of MHC class I-restricted processing of proteins (14)
questions the validity of results obtained with the 205 pro-
teasome in vitro. Reinvestigation of the same model sys-
tem, however, did not confirm the ubiquitin requirement
(28). We describe here that the same sequence alteration in
an endogenously processed protein, in an endogenously
processed peptide, and in a synthetic peptide all result in
the same relative abundance of the antigenic nonapeptide.
This provides a new line of evidence that the proteasome is
involved in antigen processing in the MHC class I path-
way. The observed cleavage preference of the proteasome
operates independently of ubiquitination.
In the MCMV model studied by us, the observed pep-
tide presentation differences are decisive for the protective
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capacity of a vaccination protocol (3) . If the proteasome
codefines the molecular basis of antigenicity, then protea-
some specificity is a key question. Short fluorogenic pep-
tides have been used to describe several peptide-hydrolyzing
activities (29, 30) . This characterization has been ques-
tioned because most peptide bonds of polypeptide sub-
strates are cleaved (25) and because cleavage is affected by
peptide size (23) . Degradation kinetics established leucine
as the first and major cleavage site in our example. The ala-
nine in position 15 of the 19-mer controls the degree of
the primary cleavage behind the leucine, and the alanine in
position 5 enhances the further degradation of the 14-mer
intermediate. The fact that alanine insertions modulate the
proteasome cleavage preference suggests that interactions
between substrate and enzyme extend over a larger area.
Concepts for a coordinated activity between distant active
sites of the enzyme complex have been proposed (23, 24).
The insertion of residues into a substrate could improve the
coordinated activity of proteolytic centers of the protease
due to spacing of two scissile bonds. Alternatively, alter-
ations of peptide conformation by exchange or insertion of
residues could improve substrate binding to the active sites
of the proteasome. Thus, local residues in the primary se-
quence and in intermediate peptides can be decisive for the
relative abundance of final products.
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